CDC25B and neoplasm: We previously reported that the BET bromodomain inhibitor JQ1, as a single agent, suppressed PDAC tumor growth in preclinical models and that tumor growth inhibition was concomitant with decreased expression of the G2 cell cycle regulator CDC25B, and increased levels of the DNA damage marker γH2AX [16,17].